Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
about
Group B streptococcus immunisation during pregnancy for improving outcomesGroup B Streptococcus vaccine: state of the artGroup B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countriesGram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary TractSurface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Vaccines: past, present and future.Molecular characterization of nontypeable group B streptococcusGroup B streptococcus and early-onset sepsis in the era of maternal prophylaxis.Anti-group B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infectionAntibody-mediated complement C3b/iC3b binding to group B Streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border.Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.Vaccination against group B streptococcus.Characterization of host immunity during persistent vaginal colonization by Group B Streptococcus.Group B streptococcal infections in elderly adults.Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching.Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier proteinDeficiency of mannose-binding lectin greatly increases antibody response in a mouse model of vaccinationTLR4-dependent adjuvant activity of Neisseria meningitidis lipid AGroup B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.Early-onset neonatal sepsis.Maternal antibody at delivery protects neonates from early onset group B streptococcal disease.An update on vaccination against group B streptococcus.Group B streptococcal infections in the newborn infant and the potential value of maternal vaccination.Strategies to develop vaccines of pediatric interest.Group B streptococcal immunisation of pregnant women for the prevention of early and late onset Group B streptococcal infection of the neonate as well as adult disease.Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.Workshop on immunizations in older adults: identifying future research agendas.Seroprevalence of Opsonophagocytic Antibodies against Serotype Ia, Ib, II, III, and V Group B Streptococcus among Korean Population.Maternal immunisation: What have been the gains? Where are the gaps? What does the future hold?
P2860
Q24186790-E4D0EAB8-F044-47B2-AB6E-D7B2CFEA3ABCQ26796438-A1F75DD8-2354-4C2C-AB71-D51CA4223B22Q28075884-D875F5A1-B991-407B-A067-7113CC0CEF9DQ28829569-F2AB8755-D6C6-444A-91F6-6DD5B5930053Q33719415-B12D3512-E336-4A1D-9989-60ECC9CD3761Q34112608-475950C7-39F7-4E64-BC5E-79D27D93AE05Q34409178-7188533D-7ACF-4414-B879-3BDD0148A290Q34719780-C981B95C-DAFF-4AF1-91C1-A95964C94577Q34985330-FF389063-331E-416E-9761-9686109CCAF1Q35042473-AF5379C6-5D69-4C9E-8F1B-5D57018703A9Q35122775-77212557-097D-4C9D-8C48-0AA9B32B39DAQ35913598-4786C655-F11A-47F5-939F-0A91D9F4669DQ36083360-C72EAFF9-27EA-43E0-8930-EA73D2EDD8C2Q36124960-98567942-AD62-47E3-88C2-D0A5A8C003BEQ36137438-18B2DBCC-56BA-4B9E-AA7C-AF56361E35F7Q36233889-A1BE0381-2C6C-4304-A0EC-16F4F5DE574EQ36557966-B2F5C793-6EFD-4FD8-B904-D1F0624C56C4Q36746962-1069F4EF-C51C-4B5F-B774-D5DB94CB7966Q37140297-33C3131F-4760-4CF2-8D3D-FB15C60C07F3Q37292481-A0881C10-A314-438D-8B75-DE6E310EF9D9Q37423240-A0A14804-6AF9-4AD4-83E1-37D8B8323F66Q37544901-0CF3E264-615C-4D80-8385-8C9BE4F70C82Q37582324-D78D94F6-F2F3-49FB-9A3F-D6D2C0DD0BB3Q37878487-6C17E1D9-0D80-48A9-8AA8-9571AD78972FQ38570903-53609181-1998-4B1E-9782-D5E83F2C091BQ38819027-C04FBEEE-FDC8-4F18-AEE5-91F5786591FFQ38844623-3005FA14-4A8F-4358-9F47-ADA6F893E16BQ46954965-DE37DE17-0476-4D3A-8F01-79205DA9C111Q51774517-7C7BACD7-BC58-40F6-AF9E-49A6F7373E69Q55011294-60A7309E-9069-4CBF-B1D8-6F8880695BA4Q59133818-04209FC0-23A2-41E6-AE11-E3383C48F867
P2860
Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Immune response of healthy wom ...... de-protein conjugate vaccines.
@en
Immune response of healthy wom ...... de-protein conjugate vaccines.
@nl
type
label
Immune response of healthy wom ...... de-protein conjugate vaccines.
@en
Immune response of healthy wom ...... de-protein conjugate vaccines.
@nl
prefLabel
Immune response of healthy wom ...... de-protein conjugate vaccines.
@en
Immune response of healthy wom ...... de-protein conjugate vaccines.
@nl
P2093
P356
P1476
Immune response of healthy wom ...... de-protein conjugate vaccines.
@en
P2093
Carol J Baker
Dennis L Kasper
Hilde-Kari Guttormsen
Lawrence C Paoletti
Marcia A Rench
Morven S Edwards
P304
P356
10.1086/382193
P407
P577
2004-03-01T00:00:00Z